NeuroRX , Acute Suicidal Ideation and Behavior (ASIB) , NRX-100 (ketamine HCl) , NRX-100 (ketamine HCl) , NeuroRx, a clinical stage biopharmacompany developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track status by the US Food and Drug Administration for its sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin enrolling patients in a pivotal trial of this sequential therapy targeting patients who are admitted to Emergency Departments with ASIB in bipolar depression.  

WuXi Biologics a global leadingopen-access biologics technology platform company offering end-to-end solutions for biologicsdiscovery, development and manufacturing,

Recipharm, the contract development and manufacturing organisation (CDMO), and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca® Depot, at Recipharm in Solna, Sweden.

AstraZeneca and Takeda Pharmaceutical Company Limited announced that they have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).

InDex Pharmaceuticals Holding AB announced that the US FDA has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients.

Epidemiologists conducting national precision medicine initiatives focused on gathering clinical research data on genetic variation among East and South Asian populations now have access to Thermo Fisher Scientific's Applied Biosystems Axiom Asia Precision Medicine Research Array.